HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
XRAY
DENTSPLY SIRONA Inc.
XRAY lost money over the past year, so it has no meaningful PE right now. Analysts expect earnings to hold roughly steady, though they disagree widely on how much.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
XRAY Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Weak |
XRAY's cash flow is currently healthy, and its revenue and profitability are stable, but its balance sheet is weak.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
XRAY PE Valuation
XRAY has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
XRAY Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Stable | |
| Stable | |
| Limited | |
| Low |
Analysts expect XRAY's earnings, revenue and profitability to hold roughly steady. However, they disagree widely on these estimates.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
XRAY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.26 | — |
| Q3 2026 | -$0.62 | +$3.73 |
| Q2 2026 | -$2.75 | +$1.92 |
| Q1 2026 | -$3.15 | +$1.32 |
| Q4 2025 | -$3.00 | +$1.48 |
| Q3 2025 | -$4.35 | -$2.28 |
| Q2 2025 | -$4.67 | -$3.81 |
| Q1 2025 | -$4.47 | -$4.03 |
| Q4 2024 | -$4.48 | -$3.86 |
XRAY is still losing money, but far less than before: $0.62 per share over the past year, against $4.82 at its worst in early 2023.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over XRAY on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
XRAY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $836M | -7.5% |
| Q2 2026 | $898M | -4.1% |
| Q1 2026 | $880M | +0.1% |
| Q4 2025 | $961M | +6.2% |
| Q3 2025 | $904M | -4.9% |
| Q2 2025 | $936M | -4.9% |
| Q1 2025 | $879M | -7.8% |
| Q4 2024 | $905M | -11% |
XRAY's revenue fell from its 2019 peak and has held roughly level since: $836M last quarter, down 7.5% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 4.4% | +29 points |
| Q2 2026 | 9.1% | +23 points |
| Q1 2026 | -4% | -11 points |
| Q4 2025 | -14% | +42 points |
| Q3 2025 | -24% | +25 points |
| Q2 2025 | -14% | -19 points |
| Q1 2025 | 7.2% | +2.8 points |
| Q4 2024 | -56% | -64 points |
XRAY has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over XRAY on cash flow, with more consistent year-over-year improvement.
XRAY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $0 | -100% |
| Q2 2026 | $55M | +244% |
| Q1 2026 | -$12M | $0 |
| Q4 2025 | $60M | +67% |
| Q3 2025 | $40M | -59% |
| Q2 2025 | $16M | -90% |
| Q1 2025 | -$12M | -$3M |
| Q4 2024 | $36M | -70% |
XRAY still generates free cash flow, though less than at its 2019 peak: $103M over the past year.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over XRAY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
XRAY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.6% | -1.3M shares |
| 1 year | -0.2% | -300K shares |
| 3 years | -5.9% | -12.6M shares |
| 5 years | -9.7% | -21.3M shares |
| Available history | -11% | -25.2M shares |
XRAY has 199M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $13M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q4 2024 | — |
| Q3 2024 | $100M |
| Q2 2024 | $150M |
| Q1 2024 | — |
| Q4 2023 | $150M |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
XRAY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 7.1x | High |
| Q2 2026 | 50.9x | High |
| Q3 2024 | 39.2x | High |
| Q2 2024 | 6.6x | High |
| Q1 2024 | 5.9x | High |
| Q4 2023 | 6.9x | High |
| Q3 2023 | 6.9x | High |
| Q2 2022 | 1.9x | Healthy |
XRAY's net debt is about 7.1 years of its operating earnings (EBITDA), up from 5.9 years a year ago.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
XRAY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.7 | Neutral |
| Stochastic | 22.9 | Neutral |
XRAY's weekly RSI is 41 (neutral) and its Stochastic is 23 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
XRAY PE vs Healthcare Sector
| Metric | XRAY | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
XRAY has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
XRAY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $9.14 | 1.1% above |
| 20 week MA | $10.7 | 14% below |
| 50 week MA | $11.3 | 18% below |
| 100 week MA | $13.2 | 30% below |
| 200 week MA | $22.7 | 59% below |
XRAY has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
XRAY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $56.8 | $51.8 | -8.8% |
| 2021 | $51.8 | $55.4 | +7% |
| 2022 | $55.4 | $31.8 | -43% |
| 2023 | $31.8 | $35.6 | +12% |
| 2024 | $35.6 | $18.9 | -47% |
| 2025 | $18.9 | $11.5 | -39% |
| 2026 YTD | $11.5 | $9.24 | -20% |
XRAY has the edge over HIMS on returns for 2026, with the stronger performance.